Search - tctmd.com

Displaying 321 - 340 of 529

Sort: Relevancy | Date

Presentation THT Abstracts 2025

Heart Failure Management Using a Risk Score From an Insertable Cardiac Monitor: The Rationale and Design of the ALLEVIATE-HF Trial

Presenter: Javed Butler

February 11, 2025

Presentation THT Abstracts 2025

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Presenter: Dmitry Yaranov

February 11, 2025

Presentation THT Abstracts 2025

Flow Restoration Leads to LV Mass Regression After DurAVR® Biomimetic THV Implant: MRI Study

February 11, 2025

Presentation THT Abstracts 2025

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

February 11, 2025

Presentation THT Abstracts 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT Abstracts 2025

Navigating Conduction Abnormalities Following Transcatheter Tricuspid Valve Replacement (TTVR): A Single Center Experience

Presenter: Tooba Salar

February 11, 2025

Presentation THT Abstracts 2025

Impact of Sitagliptin on Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction in Type 2 Diabetes Patients: A Retrospective Cohort Study

Presenter: Thitiphan Srikulmontri

February 11, 2025

Presentation THT Abstracts 2025

Outcomes of Sodium-Glucose Cotransporter 2 Inhibitor Use in Cardiac Sarcoidosis Cardiomyopathy

Presenter: Ahmed Mahmoud

February 11, 2025

Presentation THT Abstracts 2025

Impact of Obesity on Clinical Outcomes of Cardiogenic Shock Patients Treated With Advanced Mechanical Circulatory Support

Presenter: Abduljabar Adi

February 11, 2025

Presentation THT Abstracts 2025

Acute Hemodynamic Effects of Impella 5.5 in Cardiogenic Shock and Decompensated Heart Failure on Hepatorenal Function

Presenter: Gabrielle Daso

February 11, 2025

Presentation THT Abstracts 2025

Sex Differences in the Utilization and Outcomes of Advanced MCS Devices in Cardiogenic Shock

Presenter: Emily Rodriguez

February 11, 2025

Presentation THT Abstracts 2025

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT Abstracts 2025

Effect of Vericiguat on Pulmonary Artery Pressures in Heart Failure Patients: Insights From Pressure Sensor Monitoring

Presenter: Boaz Elad

February 11, 2025

Presentation THT Abstracts 2025

Use of Vericiguat in Durable Left Ventricular Assist Device Patients

February 11, 2025

Presentation THT Abstracts 2025

Success of a Nurse-Led, Virtual Care Pathway for Implementing Pulmonary Artery Pressure Monitoring for Patients With Symptomatic Heart Failure

Presenter: Timothy Fendler

February 11, 2025

Presentation THT Abstracts 2025

TRISCEND II Trial: Right Heart Failure Outcomes in Patients With Severe Tricuspid Regurgitation at One Year

Presenter: Aasim Afzal

February 11, 2025

Presentation THT Abstracts 2025

Introduction of Guideline Directed Medical Therapy (GDMT) in Acute Myocardial Infarction (AMI) Shock Patients Supported by Impella 5.5

February 11, 2025

Presentation THT Abstracts 2025

Barostim With Durable Left Ventricular Assist Device (LVAD) Therapy

Presenter: Kanika Mody

February 11, 2025

Presentation THT Abstracts 2025

The Use of Cardiac Contractility Modulation(CCM) and Durable Left Ventricular Assist Device (LVAD) for Patients With Class IV CHF

Presenter: Kanika Mody

February 11, 2025

Presentation THT Abstracts 2025

Determining Equity and Timeliness of ATTR-CM Diagnosis

Presenter: Anubodh Varshney

February 11, 2025

Advertisement

Heart Failure Management Using a Risk Score From an Insertable Cardiac Monitor: The Rationale and Design of the ALLEVIATE-HF Trial

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Flow Restoration Leads to LV Mass Regression After DurAVR® Biomimetic THV Implant: MRI Study

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Navigating Conduction Abnormalities Following Transcatheter Tricuspid Valve Replacement (TTVR): A Single Center Experience

Impact of Sitagliptin on Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction in Type 2 Diabetes Patients: A Retrospective Cohort Study

Outcomes of Sodium-Glucose Cotransporter 2 Inhibitor Use in Cardiac Sarcoidosis Cardiomyopathy

Impact of Obesity on Clinical Outcomes of Cardiogenic Shock Patients Treated With Advanced Mechanical Circulatory Support

Acute Hemodynamic Effects of Impella 5.5 in Cardiogenic Shock and Decompensated Heart Failure on Hepatorenal Function

Sex Differences in the Utilization and Outcomes of Advanced MCS Devices in Cardiogenic Shock

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Effect of Vericiguat on Pulmonary Artery Pressures in Heart Failure Patients: Insights From Pressure Sensor Monitoring

Use of Vericiguat in Durable Left Ventricular Assist Device Patients

Success of a Nurse-Led, Virtual Care Pathway for Implementing Pulmonary Artery Pressure Monitoring for Patients With Symptomatic Heart Failure

TRISCEND II Trial: Right Heart Failure Outcomes in Patients With Severe Tricuspid Regurgitation at One Year

Introduction of Guideline Directed Medical Therapy (GDMT) in Acute Myocardial Infarction (AMI) Shock Patients Supported by Impella 5.5

Barostim With Durable Left Ventricular Assist Device (LVAD) Therapy

The Use of Cardiac Contractility Modulation(CCM) and Durable Left Ventricular Assist Device (LVAD) for Patients With Class IV CHF

Determining Equity and Timeliness of ATTR-CM Diagnosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content